EAEleni Anastasiadis

Eleni Anastasiadis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eleni Anastasiadis has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Mark Emberton

    Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK

    3 shared publications
  • Benjamin Ayres

    Penile Cancer Centre, St George's Healthcare NHS Trust, London, UK

    2 shared publications
  • Jan van der Meulen

    Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK

    2 shared publications
  • Nick Watkin

    Penile Cancer Centre, St George's Healthcare NHS Trust, London, UK

    2 shared publications
  • Abbas Khizar Khoja

    Department of Urology, Croydon University Hospital NHS Trust, London, United Kingdom

    1 shared publication
  • Alex Freeman

    Department of Histopathology, University College London Hospitals NHS Foundation Trust, London, United Kingdom

    1 shared publication

Latest Publications

  • Open Access

    Erectile dysfunction: Is platelet-rich plasma the new frontier for treatment in patients with erectile dysfunction? A review of the existing evidence

    by Eleni Anastasiadis, Razna Ahmed, Abbas Khizar Khoja, Tet Yap

    Erectile dysfunction (ED) is one of the commonest disorders in adult males and affects 12–19% of men of reproductive age. Only few studies have evaluated the impact of ED on men and couples with infertility—these studies report higher rates of ED in this sub-group of men compared to the general population, with the prevalence of ED in men diagnosed with male infertility ranging from 6.7 to 61.6%. Nevertheless, ED is considered a rare cause of male infertility, accounting for about 0.4–5% of all causes of male infertility. ED remains a poorly treated condition globally and current therapies, like oral medication, offer only temporary symptomatic relief and do not influence disease progression—patients are potentially on lifelong treatment, with ED worsening over time. In contrast, regenerative medicine may potentially reverse or halt the progression of ED processes. In this article, we review the evidence for intracavernosal injections of platelet-rich plasma (PRP) in the treatment of ED.


  • Penile Mass: When Should Someone Worry and Seek Care?

    by Eleni Anastasiadis, Benjamin Ayres, Nick Watkin


  • Update on penile sparing surgery for penile cancer

    by Eleni Anastasiadis, Benjamin Ayres, Nick Watkin

    Purpose of review: Penile sparing surgery (PSS) is considered the standard of care in penile cancer where appropriate, as preservation of the penis may enable the patient to maintain urinary and sexual function. This review will focus on the latest developments over the past two years. Recent findings: In this review, we discuss the latest findings in oncological outcomes in PSS, specifically glansectomy. We also introduce technology that may be useful in improving the precision of surgical resection margins in PSS. Finally, we consider the value of patient-reported outcome measures (PROMs) and consider how research in this area can be improved. Summary: A recent study has found a correlation between local recurrences (LR) and worse overall and cancer-specific survival in glansectomy, which challenges the belief that LR do not confer worse oncological outcomes. Despite numerous studies evaluating PROMs in penile cancer/PSS, few of these studies provide quality evidence of the ‘supportive care needs’. A shift in research is required to identify those men at most risk of distress and to identify ways to support men diagnosed with penile cancer.


  • Open partial nephrectomy in renal cell cancer – Essential or obsolete?

    by Eleni Anastasiadis, Timothy O'Brien, Archana Fernando

    Since the first partial nephrectomy was first conducted 131 years ago, the procedure has evolved into the gold standard treatment for small renal masses. Over the past decade, with the introduction of minimally invasive surgery, open partial nephrectomy still retains a valuable role in the treatment of complex tumours in challenging clinical situations (e.g. hereditary renal cancer or single kidneys), and enables surgeons to push the boundaries of nephron-sparing surgery. In this article, we consider the origin of the procedure and how it has evolved over the past century, the surgical techniques involved, and the oncological and functional outcomes.


  • Incidental prostate cancer diagnosed following a transurethral resection of the prostate: A national database analysis in England

    by Eleni Anastasiadis, Jan van der Meulen, Mark Emberton

    The aim was to compare prostate cancer and all-cause mortality in patients diagnosed with prostate cancer following a transurethral resection of the prostate (TURP) (incidental prostate cancer, IPC), to men diagnosed with localised non-incidental prostate cancer (NIPC). Men diagnosed with localised prostate cancer between 2000 and 2008 were identified from the English national cancer registry. Their records were linked to the Hospital Episode Statistics (HES) database of hospital admissions in England to identify men who had a TURP. Men were considered to have IPC if prostate cancer was diagnosed less than 60 days after TURP. Mortality rates were calculated using the Kaplan–Meier method. Mortality rate ratios (RR) comparing IPC and NIPC were calculated with multivariable Poisson regression adjusting for age group, co-morbidities, year of diagnosis and radical treatment. A total of 192,960 men were included. Of these, 6666 (3.5%) had IPC and 186,294 (96.5%) NIPC. Median follow-up was 4.7 years (0.5–11.0). Ten-year prostate cancer mortality was 17.1% in IPC, 19.0% in NIPC. With adjustment, the prostate cancer-specific mortality in IPC was 30% lower than NIPC (RR 0.70, 95% CI 0.65–0.75, p<0.001), with no difference in all-cause mortality. Ten-year prostate cancer mortality in IPC was 17%. Men with IPC had lower prostate cancer-specific mortality than other prostate cancer patients.


  • What Burden of Prostate Cancer Can Radiologists Rule Out on Multiparametric Magnetic Resonance Imaging? A Sensitivity Analysis Based on Varying the Target Condition in Template Prostate Mapping Biopsies

    by Eleni Anastasiadis, Susan C. Charman, Nimalan Arumainayagam, Aslam S. Sohaib, Clare Allen, Alex Freeman, Mark Emberton, Hashim U. Ahmed


  • A novel randomised controlled trial design in prostate cancer

    by Eleni Anastasiadis, Hashim Uddin Ahmed, Clare Relton, Mark Emberton


  • Hospital admissions after transrectal ultrasound‐guided biopsy of the prostate in men diagnosed with prostate cancer: A database analysis in England

    by Eleni Anastasiadis, Jan van der Meulen, Mark Emberton

    Objectives: To investigate the complication rate within 30 days after transrectal ultrasound‐guided biopsy of the prostate in England, and to examine associated risk factors.Methods: A population‐based study was carried out using the English cancer registry linked to administrative hospital data. We included men aged 45 years and older diagnosed with prostate cancer between 2000 and 2008. A complication was considered to have occurred if men had been admitted to hospital as a result of urological causes (urinary tract infection/sepsis, hematuria and urinary retention) within 30 days of the transrectal ultrasound‐guided biopsy of the prostate. Multivariable logistic regression was carried out to estimate odds ratios, reflecting the impact of risk factors on the complication rate.Results: Of the 198 361 included men, 69% were aged between 65 and 84 years. The 30‐day complication rate was 3.7% (1.1% for urinary tract infection/sepsis, 1.4% for hematuria and 1.3% for urinary retention). The most important risk factors were age above 85 years (odds ratio 3.85, 95% confidence interval 3.18–4.67, compared with age below 55 years) and three or more comorbidities (odds ratio 3.50, 95% confidence interval 3.17–5.87, compared with no comorbidity). The overall complication rate increased over time (odds ratio 1.20, 95% confidence interval 1.08–1.34, 2008 compared with 2000), as did the complication rate as a result of urinary tract infection/sepsis (odds ratio 1.72, 95% confidence interval 1.41–2.10, 2008 compared with 2000).Conclusions: There has been an increase in the complication rate after transrectal ultrasound‐guided biopsy of the prostate in England between 2000 and 2008, predominantly as a result of infections. Age and comorbid conditions seem to represent the two most important risk factors for occurrence of post‐biopsy complications.